Context Therapeutics’ (CNTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $6.00 target price on the stock.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX opened at $1.96 on Monday. Context Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.75. The firm has a market capitalization of $147.00 million, a price-to-earnings ratio of -1.47 and a beta of 2.31. The business’s 50 day moving average price is $2.31 and its 200-day moving average price is $1.86.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. On average, sell-side analysts expect that Context Therapeutics will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC acquired a new position in Context Therapeutics in the 2nd quarter valued at $3,881,000. Driehaus Capital Management LLC acquired a new position in Context Therapeutics in the 2nd quarter valued at $4,527,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Context Therapeutics in the 2nd quarter worth $10,348,000. Affinity Asset Advisors LLC increased its stake in shares of Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the last quarter. Finally, Great Point Partners LLC acquired a new stake in shares of Context Therapeutics in the 2nd quarter worth $14,876,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.